<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771394</url>
  </required_header>
  <id_info>
    <org_study_id>905-JC-001</org_study_id>
    <nct_id>NCT00771394</nct_id>
  </id_info>
  <brief_title>Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of solifenacin succinate as add-on therapy for overactive
      bladder (OAB) symptoms in men who have been treated for benign prostatic hyperplasia (BPH)
      with tamsulosin hydrochloride for at least 6 weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study drugs are administered for 14 weeks in total, including a 2-week run-in period (single
      blind) and a 12-week treatment period (double blind). After written informed consent, study
      drugs for the run-in period are orally administered once daily after breakfast for two weeks
      to subjects who fulfill the inclusion and exclusion criteria. Then, subjects are randomized
      and orally treated with study drugs for the treatment period once daily after breakfast for
      12 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean number of urgency episodes per 24 hours</measure>
    <time_frame>at 4, 8, 12 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean number of micturitions per 24 hrs</measure>
    <time_frame>at 4, 8, 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of incontinence episodes per 24 hours</measure>
    <time_frame>at 4, 8, 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of micturitions per night</measure>
    <time_frame>at 4, 8, 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events, Laboratory Tests</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">638</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Benign Prostatic Hypertrophy</condition>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>1. Tamsulosin alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Tamsulosin + solifenacin (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Tamsulosin + solifenacin (high dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin hydrochloride</intervention_name>
    <description>oral</description>
    <arm_group_label>1. Tamsulosin alone</arm_group_label>
    <arm_group_label>2. Tamsulosin + solifenacin (low dose)</arm_group_label>
    <arm_group_label>3. Tamsulosin + solifenacin (high dose)</arm_group_label>
    <other_name>Harnal</other_name>
    <other_name>YM617</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate</intervention_name>
    <description>oral</description>
    <arm_group_label>2. Tamsulosin + solifenacin (low dose)</arm_group_label>
    <arm_group_label>3. Tamsulosin + solifenacin (high dose)</arm_group_label>
    <other_name>Vesicare</other_name>
    <other_name>YM905</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with benign prostatic hypertrophy who have been treated with tamsulosin for
             at least 6 weeks

          -  Patients with urgency episodes and frequent micturitions

          -  Written informed consent has been obtained

          -  Uroflowmetry-Q max ≥ 5 mL/sec, and Post Void Residual Volume &lt; 50 mL

        Exclusion Criteria:

          -  Patients with suspected symptoms of OAB whose onset is only transient (drug-induced,
             psychogenic, etc.)

          -  Patients with obvious stress urinary incontinence

          -  Patients with complications or who have a past history of a bladder tumor

          -  Patients with urethral stricture or bladder neck stenosis

          -  Patients with a history of surgery causing damage to the pelvic plexus

          -  Patients with history of hypersensitivity to α receptor blockers, a/b receptor
             blockers, or anticholinergic drugs

          -  Patients with orthostatic hypotension, ulcerative colitis, hyperthyroidism, dementia
             or cognitive dysfunction, Parkinson's disease, or cerebrovascular disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Touhoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to results on JAPIC - enter JapicCTI-R120267 in the JapicCTI-RNo. field</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vesicare</keyword>
  <keyword>Solifenacin succinate</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>Overactive Bladder</keyword>
  <keyword>BPH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

